State Street’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.4M | Buy |
1,955,844
+44,153
| +2% | +$712K | ﹤0.01% | 1871 |
|
|
2025
Q4 | $30.9M | Buy |
1,911,691
+336,195
| +21% | +$4.45M | ﹤0.01% | 2016 |
|
|
2025
Q3 | $19.2M | Buy |
1,575,496
+225,957
| +17% | +$3.12M | ﹤0.01% | 2280 |
|
|
2025
Q2 | $15.3M | Buy |
1,349,539
+255,896
| +23% | +$3.13M | ﹤0.01% | 2334 |
|
|
2025
Q1 | $12.6M | Sell |
1,093,643
-297,220
| -21% | -$3.03M | ﹤0.01% | 2383 |
|
|
2024
Q4 | $11.8M | Buy |
1,390,863
+119,254
| +9% | +$1.24M | ﹤0.01% | 2532 |
|
|
2024
Q3 | $14.7M | Buy |
1,271,609
+515,179
| +68% | +$6.48M | ﹤0.01% | 2379 |
|
|
2024
Q2 | $8.91M | Buy |
756,430
+162,257
| +27% | +$1.89M | ﹤0.01% | 2627 |
|
|
2024
Q1 | $7.05M | Buy |
594,173
+57,071
| +11% | +$761K | ﹤0.01% | 2770 |
|
|
2023
Q4 | $6.58M | Buy |
537,102
+77,756
| +17% | +$707K | ﹤0.01% | 2814 |
|
|
2023
Q3 | $4.42M | Buy |
459,346
+13,171
| +3% | +$135K | ﹤0.01% | 2977 |
|
|
2023
Q2 | $4.02M | Buy |
446,175
+26,914
| +6% | +$248K | ﹤0.01% | 3101 |
|
|
2023
Q1 | $3.3M | Buy |
419,261
+15,301
| +4% | +$114K | ﹤0.01% | 3145 |
|
|
2022
Q4 | $2.73M | Sell |
403,960
-17,859
| -4% | -$95.7K | ﹤0.01% | 3280 |
|
|
2022
Q3 | $6.12M | Buy |
421,819
+11,567
| +3% | +$162K | ﹤0.01% | 2961 |
|
|
2022
Q2 | $4.04M | Sell |
410,252
-528,615
| -56% | -$5.83M | ﹤0.01% | 3198 |
|
|
2022
Q1 | $13.8M | Sell |
938,867
-113,109
| -11% | -$1.63M | ﹤0.01% | 2642 |
|
|
2021
Q4 | $13.9M | Buy |
1,051,976
+8,148
| +0.8% | +$130K | ﹤0.01% | 2712 |
|
|
2021
Q3 | $18.2M | Sell |
1,043,828
-356,673
| -25% | -$7.23M | ﹤0.01% | 2539 |
|
|
2021
Q2 | $33.6M | Buy |
1,400,501
+809,029
| +137% | +$21.2M | ﹤0.01% | 2137 |
|
|
2021
Q1 | $15.2M | Buy |
591,472
+323,818
| +121% | +$8.51M | ﹤0.01% | 2522 |
|
|
2020
Q4 | $5.08M | Buy |
267,654
+7,089
| +3% | +$122K | ﹤0.01% | 2950 |
|
|
2020
Q3 | $3.28M | Buy |
260,565
+8,795
| +3% | +$110K | ﹤0.01% | 2994 |
|
|
2020
Q2 | $3.05M | Buy |
251,770
+6,769
| +3% | +$72K | ﹤0.01% | 3004 |
|
|
2020
Q1 | $1.87M | Buy |
245,001
+13,060
| +6% | +$176K | ﹤0.01% | 3089 |
|
|
2019
Q4 | $4.13M | Buy |
231,941
+3,790
| +2% | +$49.5K | ﹤0.01% | 2925 |
|
|
2019
Q3 | $2.65M | Buy |
228,151
+27,325
| +14% | +$441K | ﹤0.01% | 3115 |
|
|
2019
Q2 | $4.45M | Buy |
200,826
+192,251
| +2,242% | +$4.51M | ﹤0.01% | 2894 |
|
|
2019
Q1 | $245K | Buy |
+8,575
| New | +$186K | ﹤0.01% | 3549 |
|
|
2016
Q2 | – | Sell |
-7,820
| Closed | -$69K | – | 3750 |
|
|
2016
Q1 | $69K | Sell |
7,820
-2
| -0% | -$36 | ﹤0.01% | 3590 |
|
|
2015
Q4 | $399K | Hold |
7,822
| – | – | ﹤0.01% | 3377 |
|
|
2015
Q3 | $394K | Buy |
7,822
+2,253
| +40% | +$192K | ﹤0.01% | 3375 |
|
|
2015
Q2 | $557K | Buy |
+5,569
| New | +$553K | ﹤0.01% | 3354 |
|
Other funds holding KALV
VA
FLSM
SCM
TCM
SCM
VPC
State Street's KALV Position: Q1 2026 in Review
State Street increased its KalVista Pharmaceuticals (KALV) stake by 2.3% in Q1 2026, buying an estimated $712K and bringing the position to 1,955,844 shares worth $39.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.
State Street first reported a position in KALV in Q2 2015 and has held it in 33 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.
- State Street held 1,955,844 shares of KalVista Pharmaceuticals worth $39.4M as of Q1 2026.
- State Street bought 44,153 KalVista Pharmaceuticals shares in Q1 2026, an estimated $712K.
- KalVista Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1871 holding.
- State Street first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
- 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.